Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future
Authors:
- François-Joseph L. MuratFMFrançois-Joseph L. Murat
- Albert GeletAGAlbert Gelet
- 1 March 2008
- journal article
- review article
- Published by Springer Nature in Current Urology Reports
- Vol. 9 (2) , 113-121
Abstract
Based on a review of recently published articles, we evaluated the current status of high-intensity focused ultrasound (HIFU) as a primary treatment option for localized prostate cancer and as a salvage therapy when radiation has failed. With mid-and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 90%, and an excellent morbidity profile, primary HIFU appears to be a valid alternative to active surveillance protocols in low-risk patients and standard therapies in patients with life expectancies of 10 or fewer years. Moreover, HIFU has a considerable potential for local-only recurrence after radiation failure. HIFU is a recent technology, and many improvements will undoubtedly expand its future indications and use for the management of prostate cancer.Keywords
This publication has 43 references indexed in Scilit:
- Transrectal high-intensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imagingEuropean Journal of Radiology, 2007
- Real‐time adaptive methods for treatment of mobile organs by MRI‐controlled high‐intensity focused ultrasoundMagnetic Resonance in Medicine, 2007
- Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly MenJAMA, 2006
- Das Lokalrezidiv des Prostatakarzinoms nach kurativer TherapieDer Urologe, 2006
- Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancerWorld Journal of Urology, 2006
- Micro-Focal Prostate Cancer: A Comparison of Biopsy and Radical Prostatectomy Specimen FeaturesEuropean Urology, 2005
- Positron Emission Tomography/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml?Molecular Imaging and Biology, 2005
- Changing demography of prostate cancer in AsiaEuropean Journal of Cancer, 2005
- The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resectionCurrent Urology Reports, 2003
- Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1999